Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NOVANTRONE vs AGRYLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mitoxantrone is a synthetic anthracenedione derivative that intercalates with DNA and inhibits topoisomerase II, leading to DNA strand breaks and inhibition of DNA and RNA synthesis. It also disrupts DNA repair and replication, and has immunosuppressive effects through inhibition of B cell, T cell, and macrophage function.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
Treatment of acute nonlymphocytic leukemia (ANLL) in adults (in combination with other agents),Treatment of advanced hormone-refractory prostate cancer (in combination with corticosteroids),Treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (to reduce neurologic disability and frequency of clinical relapses)
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
12 mg/m2 IV over 5-15 minutes once daily on days 1-3 of a 28-day cycle, or as a single dose of 12-14 mg/m2 IV every 21 days. For acute nonlymphocytic leukemia, 12 mg/m2 IV daily for 3 days with cytarabine.
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
Terminal elimination half-life: 23-215 hours (mean ~37 hours). The long half-life reflects extensive tissue distribution and slow elimination, allowing weekly dosing.
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
Mitoxantrone is extensively metabolized in the liver via oxidation and conjugation, primarily by cytochrome P450 enzymes, forming inactive metabolites. Elimination is mainly via the hepatobiliary system with fecal excretion; small amounts are excreted renally.
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Primarily hepatic (biliary/fecal) elimination: ~25% as unchanged drug and metabolites in feces over 5 days; renal excretion accounts for ~11% (6-11%) as unchanged drug. Less than 10% excreted unchanged in urine.
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
~78% bound to plasma proteins (primarily albumin).
82–88% bound to plasma proteins (primarily albumin).
Mean Vd: 8-22 L/kg (range 6-44 L/kg). Large Vd indicates extensive tissue distribution and binding to intracellular components.
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Intravenous: 100% (only route of administration). Oral bioavailability is <5% and not clinically relevant; no other routes used.
Oral: 65–80% (median 73%)
No dose adjustment required for GFR >50 m L/min. For GFR 10-50 m L/min: administer 75% of normal dose. For GFR <10 m L/min: administer 50% of normal dose.
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25%. Child-Pugh Class C: reduce dose by 50%.
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
Safety and efficacy not established; not recommended for pediatric use.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
Monitor cardiac function closely due to increased risk of cardiotoxicity. Higher risk of myelosuppression; consider lower initial doses based on renal function (see renal adjustment).
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
1. Mitoxantrone should be administered under the supervision of a physician experienced in the use of cancer chemotherapy agents. 2. Cardiac toxicity, including congestive heart failure, can occur and may be cumulative; risk increases with prior anthracycline use, mediastinal radiotherapy, pre-existing cardiac disease, or concomitant cardiotoxic drugs. 3. Secondary acute myeloid leukemia (AML) has been reported in patients treated with mitoxantrone-containing regimens. 4. Severe myelosuppression will occur.
None
Cardiotoxicity: Monitor left ventricular ejection fraction (LVEF) before and during therapy; cumulative dose limit of 140 mg/m² in multiple sclerosis patients.,Myelosuppression: Severe neutropenia, thrombocytopenia, and anemia; monitor complete blood counts regularly.,Secondary malignancies: Increased risk of AML and myelodysplastic syndrome.,Hepatic impairment: Dose reduction may be necessary; monitor liver function.,Renal impairment: Use with caution; adjust dose if severe.,Immunosuppression: Increased risk of infections; avoid live vaccines.,Pregnancy: Can cause fetal harm; advise effective contraception.,Extravasation: Can cause tissue necrosis; administer via IV with care.
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
Hypersensitivity to mitoxantrone or any component of the formulation,Significant pre-existing bone marrow suppression (e.g., baseline neutrophil count <1500/mm³, platelet count <50,000/mm³),Patients with clinically significant cardiac disease (e.g., myocardial infarction within 6 months, unstable angina, severe heart failure)
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
No known food interactions. Maintain adequate hydration to prevent tumor lysis syndrome. Avoid grapefruit juice as it may theoretically interfere with metabolism, though not clinically significant.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
Mitoxantrone is teratogenic in animals and is classified as Pregnancy Category D. First trimester exposure is associated with increased risk of spontaneous abortion and major congenital malformations. Second and third trimester exposure may cause fetal growth restriction, myelosuppression, and cardiac toxicity. Use during pregnancy is contraindicated unless the potential benefit outweighs the risk.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
Mitoxantrone is excreted into human breast milk; the milk-to-plasma ratio is not well characterized. Due to the potential for serious adverse reactions in nursing infants, including immunosuppression and cardiotoxicity, breastfeeding is contraindicated during therapy and for at least 1 month after the last dose.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
No specific dose adjustments are established for pregnancy. However, pharmacokinetics may be altered due to increased plasma volume and renal clearance. Dose adjustment based on body surface area and close monitoring for toxicity are recommended. Use lowest effective dose and consider alternative therapies if possible.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
Mitoxantrone is a topoisomerase II inhibitor and anthracenedione; cumulative lifetime dose should not exceed 140 mg/m² due to dose-dependent cardiotoxicity. Pre-treatment LVEF must be assessed and monitored regularly. Administration requires cardiac monitoring during infusion due to risk of arrhythmias.
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
Report any shortness of breath, cough, or swelling of ankles/feet immediately as these may indicate heart problems.,Urine may turn blue-green for 24-48 hours after infusion; this is harmless.,Avoid live vaccines during treatment and for 6 months after.,Use effective contraception during and for at least 4 months after therapy due to risk of fetal harm.,Notify your doctor if you experience easy bruising, bleeding, fever, or signs of infection.
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NOVANTRONE vs AGRYLIN, answered by our medical review team.
NOVANTRONE is a Antineoplastic Agent that works by Mitoxantrone is a synthetic anthracenedione derivative that intercalates with DNA and inhibits topoisomerase II, leading to DNA strand breaks and inhibition of DNA and RNA synthesis. It also disrupts DNA repair and replication, and has immunosuppressive effects through inhibition of B cell, T cell, and macrophage function.. AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NOVANTRONE and AGRYLIN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NOVANTRONE is: 12 mg/m2 IV over 5-15 minutes once daily on days 1-3 of a 28-day cycle, or as a single dose of 12-14 mg/m2 IV every 21 days. For acute nonlymphocytic leukemia, 12 mg/m2 IV daily for 3 days with cytarabine.. The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NOVANTRONE and AGRYLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NOVANTRONE is classified as Category C. Mitoxantrone is teratogenic in animals and is classified as Pregnancy Category D. First trimester exposure is associated with increased risk of spontaneous abortion and major conge. AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.